使用蛋白质组学来识别基于他类药物对缺血性心脏病的益处的机制
Jie V Zhao1,2, Junmeng Zhang3
1School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. janezhao@hku.hk.
NPJ cardiovascular health
|March 3, 2026
概括
对于缺血性心脏病 (IHD) 至关重要的他类药物,其机制尚不清楚. 这项研究确定了PLA2G7作为一种与较高的IHD风险相关的蛋白质,可能揭示了他类药物如何有益于患者,并指导精准医学.
科学领域:
- 心血管遗传学 心血管遗传学
- 蛋白质组学是指蛋白质组学.
- 药物基因组学 药物基因组学
背景情况:
- 缺血性心脏病 (IHD) 是全球主要的死亡原因.
- 类药物是IHD的主要治疗方法,但它们的精确机制仍然难以捉摸.
- 了解这些机制对于推进心血管护理的精准医学至关重要.
研究的目的:
- 阐明在IHD中他类药物的益处的蛋白质水平机制.
- 为了确定受到他类药物影响的特定蛋白质及其随后对IHD风险的影响.
- 探索他类药物受影响的蛋白质在常见的IHD并发症中的作用.
主要方法:
- 采用了双步门德尔随机化 (MR) 方法.
- 全基因组关联研究 (GWAS) 确定了受到他类药物影响的蛋白质 (UKB-PPP,deCODE).
- 在MR分析中,评估了已识别的蛋白质与IHD风险之间的关联 (CARDIoGRAMplusC4D,FinnGen,deCODE).
主要成果:
- 发现九种蛋白质受到他类药物的影响.
- 确定PLA2G7是一种与增加IHD风险相关的蛋白质.
- 与他类药物相关的PLA2G7与糖尿病,慢性病 (CKD) 或估计的淋巴细胞过率 (eGFR) 没有显著的关联.
结论:
- PLA2G7与他类药物对IHD的益处机制有关.
- 鉴定了七种新型蛋白质受到他类药物的影响,扩大了我们对它们分子作用的理解.
- 这些发现为开发新的治疗策略和推进IHD的精准医学提供了洞察力.
相关概念视频
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...